1 / 85

William 2001

Diabetes . William 2001. Classification Gestational diabetes Overt diabetes Contraception. In 1900  ↑ infertility ↑ maternal mortality ↑ perinatal mortality = 40% In 1922  insulin discovery  ↓ infertility

hua
Télécharger la présentation

William 2001

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Diabetes William 2001

  2. Classification • Gestational diabetes • Overt diabetes • Contraception

  3. In 1900  ↑ infertility ↑ maternal mortality ↑ perinatal mortality = 40% In 1922  insulin discovery  ↓ infertility ↓ maternal mortality, but same perinatal mortality In 1949  White classification ↑ severity = ↑ perinatal mortality early termination by CS+diabeticcontrol  ↓ perinatal mortality to 15% Now  perinatal mortality = near normal introduction

  4. Classification during Pregnancy • Diagnosis of Overt Diabetes during pregnancy • Detection of Gestational Diabetes - Screening - Diagnostic criteria classification

  5. Type I • Immune mediated • Develop in genetically susceptible persons • Triggered by viral infectioninflammatory insulitis autoimmune antibodies against β–cells cell destruction • Associated with HLA D on chromosome 6 • Low vertical transmission rate • Concordance rate in monozygotic twins = < 50% classification

  6. Type II Familial No HLA association Concordance rate in monozygotic twins 100% 40% of sibling+ 1/3 offspring abnormal GTT Pathophysiology: • Abnormal insulin secretion • Insulin resistance in the target cell Obesity  peripheral insulin resistance  exhaustion of β-cells

  7. type Itype II Age of onset < 40 >40 Habitus normal to thin obese Genetic locus chromosome 6 unknown P. Insulin ↓ to absent normal to ↑ P.Glucagon ↑, suppressible ↑, resistant Insulin ttt responsive responsive/ resistant Sulfonylurea unresponsive responsive Acute ketoacidosishyperosmolar complication coma

  8. OnsetFBSPP 2hourstreatment A1 Gestational <10 <120 diet A2 Gestational >105 >120 insulin age of onsetdurationcomplication B >20 <10 - insulin C 10-19 10-19 - “ D <10 >20 benign retinopathy “ F any nephropathy “ R any proliferative retinopathy “ H any heart disease “ Classification during pregnancy

  9. Diabetes is the most common medical complication of pregnancy. % = 2.6 of all live birth, 90% GD, 10%OD Diagnosis: • RBS > 200 mg/dL + symptoms: = polyuria = polydipsia = unexplained weight loss • FBS ≥ 126 mg/dL , because ≥ 126  dramatic ↑ retinopathy Diagnosis of overt diabetes

  10. Risk of OD ↑ in the presence of: • Persistent glucosurea • Strong family history • Large infant • Unexplained fetal death A +ve dip-stick test = • Augmented glomerular filtration, or • Glucosurea  evaluate

  11. Definition: Carbohydrate intolerance with onset or 1st recognition during pregnancy. Some of GD are overt diabetes 1st recognized during pregnancy. Study: Fasting hyperglycemia < 24 weeks pregnancy outcome as class B = OD Early hyperglycemia = high risk group Detection of gestational diabetes

  12. 2 step test: 50 gm glucose  1 hour if ↑blood glucose  diagnostic 100 gm glucose • 1 step test: diagnostic 100 gm glucose 1 hour  sample Devices avoided in screening: • Reflectance photometer • Glucometer screening

  13. In 50 gm 1 hour blood sample: • 140 mg/dL identify 80% of GD  +ve in 14 – 18 % of women • 130 mg/dL identify 90% of GD  +ve in 20 – 25 % of women 50 gm test: Abnormal results are 83% reproducible Normal results are 90% reproducible

  14. Low risk If all are +ve no routine screening: • No DM in 1st degree relative • No ethnic risk • < 25 years • Normal weight before pregnancy • No poor obstetric outcome • No history of abnormal GTT Selective screening

  15. Average risk If 1 is +ve screen at 24-28 weeks = Average: African, South and East Asian, Native Americans and Hispanics = High: • Marked obesity • Strong family history • Previous GD • Glucosuria

  16. High risk If 1 is +ve screen as soon as possible: = If GD is not diagnosed  blood glucose testing should be repeated at: • 24 - 28 weeks = At any time when the patient develops: • Symptoms • Signs

  17. ACOG 1994 criteria for diagnosis of GD using 100gm glucose taken orally. GD is diagnosed when any 2 values are met or exceeded. National DiabetesCarpenterData Group&Coustan (1979) (1982) Fasting 105 95 1 hr 190 180 2 hr 165 155 3 hr 145 140 Diagnostic criteria

  18. Carpenter criteria: • ↑ 54% the number of pregnant women with diagnosis of GD • minimally affect % macrosomia • ↑ cost 75 gm test: used in Europe 100 gm test + 3 hour pp: used in USA 70% of physician use: National Diabetes Data Group criteria

  19. Maternal and fetal effects • Management • Obstetric management • Postpartum consequences Gestational diabetes

  20. GD induced by pregnancy may be : • Exaggerated physiological changes • Type II 1st recognized during pregnancy Study: % of undiagnosed DM between 20-44 years ♀ = % of GD Study: Abnormalities of glucose metabolism in GD = abnormalities in overt D

  21. Diagnosis of GD = • need for ↑ surveillance • need for pp testing % of fetal death in treated ♀ = normal The only problem is: ↑ fetal size  birth injures 50% of GD  overt D within 20 years + ↑ % of DM + ↑ % of obesity in their offspring

  22. Fetal anomalies are not ↑ in A1 & A2 Fetal death  normal in A1 as overt D in A2 Macrosomia: • Avoid difficult labor • Characterize the fetus of diabetic mothers • Affect all organs of the fetus except the brain • Differ from other causes of macrosomia: - ↑ shoulder and trunk ↑ shoulder dystocia - ↑ subscapular and triceps skin fold diameter  ↑ % of CS due to CPD Maternal and fetal effects

  23. % of shoulder dystocia in A1 = 3% Pathogenesis: Maternal hyperglycemia  maternal hyperinsu-linemia  fetal hyperinsulinemia  neonatal hypoglycemia ≤ 35 mg/dL (in preterm fetuses less value due to ↓ glycogen stores) % of neonates requiring IV glucose in GD = 4%

  24. Insulin: Produced by β-cells in the pancreas >20 weeks  Stimulate somatic growth and adiposity Insulin-GF I, insulin-GF II: Pro-insulin-like peptides Produced by nearly every cell Potent stimulators for cell division&differentiation Cord blood level of: Insulin, IGF-I, IGF-II correlate with birth weight

  25. Maternal obesity is more important risk factor than glucose intolerance in GD Study: 8% of women > 250 pounds have GD < 1% of women < 200 pounds Study: ↑ risk of GD in women with truncal obesity

  26. ACOG: If FBS ≥ 105 mg/dL 2h PP ≥ 120 mg/dL insulin American Diabetes Association: If diet cannot keep capillary FBS ≤ 95 mg/dL 2 h pp ≤ 120 mg/dL insulin Diet Aim: • supply necessary nutrients • control glucose level • prevent starvation ketosis management

  27. Caloric restriction in overweight women: 1200 - 1800 Kcal/day • ↓hyperglycemia • ↓ triglycerides • No ↑ in ketonuria • Improve glucose control • ↓ need for insulin • ↓ macrosomia • ↓ maternal weight gain

  28. Safety unknown, not recommended by ACOG Exercise • Upper cardiovascular exercises • Improve glycemic control + diet • Effect appears after 4 weeks

  29. Indicated if diet cannot persistently keep FBS ≤ 105 mg/dL Hospitalization to: • Titrate insulin dosage • Educate the patient Dose 20–30 IU/day once before breakfast • 2/3 intermediate acting • 1/3 short acting insulin

  30. Study: Post-prandialsurveillance is superior to pre-prandial surveillance  • ↓ CS • ↓ neonatal hypoglycemia • ↓ macrosomia Study: Both are equally important Study: Treatment by insulin+diet↓birth weight

  31. Study: Insulin + diet  No ↓ birth weight Study: Strict glucose control # routine antenatalcare  little effect on: • Birth weight • Operative delivery • Neonatal complications

  32. Study: Glucometer 7 times/day  • ↓ Macrosomia • ↓ CS • ↓ shoulder dystocia Oral hypoglycemics: Not recommended by ADA, Althoughno ↑ neonatal complications were detected in one study

  33. A1 Spontaneous normal delivery No early induction No antepartum fetal testing Study: Elective induction in A1 ↓ shoulder dystocia to 0.7% # 2.2% in spontaneous delivery A2  as overt diabetes Obstetric management

  34. As ½ GD  overt diabetes within 20 years, all GD most be tested 6-12 weeks pp If normal GTT  tested/3 years Patient and physician compliance = 30% A2 or insulin treatment < 24 weeks = DM pp Long - term risks in GD: • Type II DM • CVD due to ↑ lipids • HTN • Abdominal obesity Post-partum consequences

  35. Risk is associated with: • Obesity • HTN • ↑ triglycerides Obese womenchange life style/control weight Recurrence of GD = 60% Even if next pregnancy with normal GTT  no improvement of pregnancy outcome as: • birth weight • macrosomia • neonatal complications

  36. Fetal effects • Neonatal effects • Maternal effects • Management Overt diabetes

  37. Successful outcomes are related to: • Diabetic control • Intensity of underlying CVD/RD Complications: • Preeclampsia 21% • PTL 25% • Macrosomia 20% • Growth restriction 1% • Unexplained fetal death 2% • Perinatal mortality 3%

  38. Abortion PTL Malformation Unexplained fetal death Hydramnios Fetal effects

  39. Perinatal mortality ↓ due to: • Maternal glucose control • Improved fetal surveillance • ICU % now = 2 – 4 % Modern intervention did not ↓: • Chromosomal abnormalities • Unexplained fetal death

  40. I - Abortion: Type I = 24% Associated with poor glycemic control in the 1st trimester Risk ↑ in: • Hg A1 > 12% • Persistent preprandial glucose > 120 mg/dL

  41. II - PTL Spontaneous PTL = 9% # 4.5% Induced PTL = 7% # 2.0% III – Malformation Type I = 5 – 10 % = ½ perinatal mortality in DM Chromosomal anomalies are not ↑

  42. Severity of malformation ↑ by: • Poor early control • Poor preconceptional control Risk of malformation ↑ in: • ↑ Hg A1 • Vasculopathy • Duration > 10 years

  43. Studies: • ↓ Hg A1 is associated with ↓ malformation • Normal Hg A1 does not guarantee absence of malformation • ↑ Hg A1 is not a risk factor for malformation • ↓ preconceptional Hg A1 is associated with 5% malformation # 9% • Strict preconceptionalglycemic control is associated with 1.2% malformation # 11%

  44. ↑ initial glucose level: ↑ single organ anomalies ↑↑ initial glucose level:  ↑ multiple organ anomalies Most common single organ anomalies: • Heart 38% • Ms/skeletal 15% • CNS 10%

  45. Animal studies: • Vit E • Antioxidants • Lipoic acid When given to pregnant rats↓ anomalies Mechanisms: • ↑glucose ↑free oxidative radicals=toxic • ↑glucose ↓specific gene activity  ↓arachidonicacid  NTD

  46. IV – Unexplained fetal death = 1% usually > 35 weeks & large Case: Cord blood show ↓ pH ↑ PHO2 ↑ lactate ↑ erythropoietin = ↑ glucose  chronic aberrations in O2 and metabolite transport

  47. Case: • Macrosomia • Hydramnios • Acidemic fetus • Hydropic placenta ( edema of chorionic villi )  ↓transport of O2

  48. Severe preeclampsia and vasculopathy in advanced ODplacental insufficiency Ketoacidosis can also cause fetal death V – Hydramnios ↑ glucose  ↑ AF glucose  hydramnios

  49. Respiratory distress Hypoglycemia Hypocalcaemia Hyperbilirubinemia Cardiac hypertrophy Cognitive development Inheritance Altered growth neonatal effects

More Related